Effects of flow rate modifications on reported @entity1337 and quality of life in XXXX @entity1 treated with continuous intrathecal drug therapy.

@entity1 @entity1337 @entity148 @entity158 @entity1118
OBJECTIVE: We compared the @entity1337 and the quality of life of a constant daily dose of intrathecal drug administered at different flow rates in @entity1 treated for @entity1118 . We postulate that the quality of the @entity1337 , at the same daily dose, will show an infusion rate dependent pattern with decreased @entity158 at higher flow rates. @entity1 : Twenty consecutive @entity1 on stable intrathecal treatment were included in a double-blind three-period crossover study where the same daily dose was administered at single, double, and quadruple flow rates in a randomized sequence. OUTCOMES MEASURES:     The mean daily @entity158 score and the quality of life (EuroQol measure of health outcome [EQ-5D]) were measured following each flow rate change, after 1 week of stabilization. Results.    Visual analog scale (VAS) scores remained unchanged with all flow rates. Compared with the lowest flow rate, the EQ-5D index decreased with double and even more with quadruple flow rate, suggesting a clinically relevant worsening of the health state with higher flow rates. Adverse events were equally distributed in all groups. CONCLUSION: @entity158 VAS did not significantly change with flow rate. This is consistent with preclinical data showing very limited increase in drug distribution in the cerebrospinal fluid with much larger flow rate augmentation. However, the quality of life decreased consistently as the flow rate increased. This was entirely due to a worsening of the @entity158 and @entity148 dimension of the EQ-5D questionnaire, caused presumably by a slight increase in @entity158 rather than adverse events. We suggest that at higher flow rates increased drug dilution results in a decreased effect at the receptor site.
